Abstract: An object of this invention is to provide a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction, and a composition for ameliorating learning disorders. Provided is a composition comprising a combination of a TRH analog and arundic acid.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
November 10, 2020
Assignee:
BRIVENTION PHARMACEUTICAL (SHANGHAI) INC.
Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.
Type:
Grant
Filed:
December 13, 2017
Date of Patent:
September 15, 2020
Assignee:
Metabolic Technologies, Inc.
Inventors:
John Rathmacher, Naji Abumrad, Shawn Baier
Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.
Type:
Grant
Filed:
June 29, 2015
Date of Patent:
August 4, 2020
Assignee:
The Regents of the University of California
Inventors:
Jing Huang, Randall M. Chin, Xudong Fu, Heejun Hwang, Karen Reue, Laurent Vergnes, Meisheng Jiang, Brett E. Lomenick, Xiang Yin, Mansoureh Eghbali, Jingyuan Li, Samuel Wheeler French, Ronik Khachatoorian
Abstract: The present invention concerns a pharmaceutical composition comprising formic acid and at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid, citric acid, preferably ethyl lactate, for the topical treatment of warts.
Abstract: An example method of treating a medical issue includes applying a composition to a skin area corresponding to a location afflicted with the medical issue. The composition includes a blend of Cannabidiol (CBD) oil and Cannabinol (CBN) oil fortified with curcumin from turmeric, Boswellic acid, and polycyclic terpenes from Boswellia serrata. The medical issue includes at least one of osteoarthritis, joint pain associated with natural causes or injury, reduced joint function and flexibility after injury or other causes, and photo-aging. A composition including a blend of pure CBD oil and CBN oil fortified with curcumin from turmeric and Boswellic acid along with polycyclic terpenes from Boswellia serrata is also disclosed.
Abstract: The present invention relates to a lactate powder, more particularly a lactate powder having a lactate content of at least 20 wt. % and a water content of less than 3.5 wt. %, said powder comprising calcium cations as well as sodium cations. According to the invention, a calcium lactate powder combining high stability with excellent water dissolution properties can be obtained even though anhydrous calcium lactate represents the bulk of the powder if the powder additionally contains a certain amount of sodium lactate. The inventors have found that the presence of sodium lactate greatly improves the dissolution behavior of the anhydrous calcium lactate while maintaining the storage stability of the powder. The present inventors also established that the dissolution behavior of the powder can be further improved by the addition of a fast-dissolving carbohydrate material.
Type:
Grant
Filed:
July 31, 2013
Date of Patent:
May 26, 2020
Assignee:
PURAC BIOCHEM B.V.
Inventors:
Kees Van Der Voort Maarschalk, Heny Kusumawardani
Abstract: The invention provides methods and compositions for reducing the percentage of body fat in an animal or human and increasing the level of adiponectin in an animal or human. Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
Abstract: Methods for modifying neuronal functional activity and/or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.
Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
March 24, 2020
Assignee:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Abstract: The disclosure concerns a medical kit arranged with componentry for fluorescein sodium (FNa)-based diagnosis and trichloroacetic acid (TCA)-based treatment of neoplastic tissue, and related methods for utilizing aspects of the medical kit.
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
March 17, 2020
Assignee:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Abstract: A pharmaceutical composition or dietary supplement having a muscle-relaxant and anti-inflammatory activity is described, which is effective in the treatment of muscle, bone, articular and tendon pathologies, comprising, as active ingredients, a combination of magnesium, at least one ketoboswellic acid and L-tryptophan.
Type:
Grant
Filed:
August 18, 2015
Date of Patent:
March 10, 2020
Assignee:
Kolinpharma S.p.A.
Inventors:
Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
Abstract: An exfoliating dentifrice composition is described that contains a plurality of granules and an orally acceptable vehicle. The granules include at least one polymeric binding agent. The composition includes at least one abrasive agent having an average particle diameter of 0.01 mm to 4 mm. Also included are methods of exfoliating an oral cavity soft tissue by use of the composition.
Type:
Grant
Filed:
April 2, 2009
Date of Patent:
December 31, 2019
Assignee:
Colgate-Palmolive Company
Inventors:
Thomas Boyd, Evangelia Arvanitidou, Joe Vazquez, Ying Yang, Qing Claire He, Mary Horchos
Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
Type:
Grant
Filed:
December 5, 2018
Date of Patent:
November 12, 2019
Assignee:
AXCELLA HEALTH INC.
Inventors:
Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt
Abstract: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
Abstract: Compositions and methods for the disinfection of surfaces are provided. The compositions include an alcohol and a peracid. The disinfectant composition is characterized by a pH of no more than about 5. Broad spectrum efficacy is achieved, and synergistic activity is exhibited against bacterial and fungal spores, including Clostridium difficile spores. The compositions and methods are also useful against conformationally altered prions, bacteria, fungi, and viruses.
Type:
Grant
Filed:
April 6, 2018
Date of Patent:
September 10, 2019
Assignee:
GOJO Industries, Inc.
Inventors:
James Edmund Bingham, Christopher M. Fricker, Michael J. Dolan
Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
July 23, 2019
Inventors:
Stephen J. Petti, Samn Raffaniello Petti
Abstract: The present invention provides a pharmaceutical or health functional food containing, as an active ingredient, a complex extract of Crataegi Fructus and Citri Pericarpium. The complex extract has the effects of reducing body weight and lipids in blood vessels.
Type:
Grant
Filed:
June 21, 2013
Date of Patent:
July 16, 2019
Assignee:
NEUMED
Inventors:
Juyeon Park, Dong Wook Lim, Mikyung Song
Abstract: A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming the resulting mixture into lozenges each containing a therapeutically effective amount of said NSAID salt/NSAID mixture. The present application discloses the corresponding NSAID-containing lozenge compositions and their use for the manufacture of a medicament for treating sore throat.
Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
Type:
Grant
Filed:
June 4, 2018
Date of Patent:
June 18, 2019
Assignee:
Ecolab USA Inc.
Inventors:
Junzhong Li, Richard K. Staub, David D. McSherry, Keith G. Lascotte, Steven J. Lange, Frank Everts
Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
Type:
Grant
Filed:
August 29, 2014
Date of Patent:
June 4, 2019
Assignees:
The Wistar Institute of Anatomy and Biology, Drexel University
Inventors:
Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
Abstract: The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, mania, migraine, Alzheimer's disease, Parkinson's disease or stroke.
Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.
Type:
Grant
Filed:
February 2, 2016
Date of Patent:
April 23, 2019
Assignee:
SICHU JIUZHANG BOPLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
Inventors:
Jie Zhang, Xiaoguang Chen, Jun Huang, Wang Huang
Abstract: The present invention relates generally to methods for forming peroxyformic acid, comprising contacting formic acid with hydrogen peroxide. The methods for forming peroxyformic acid can include adding formic acid with a relatively lower concentration of hydrogen peroxide, or adding formic acid to a peroxycarboxylic acid composition or forming composition to react with hydrogen peroxide in the compositions. The present invention also relates to peroxyformic acid formed by the above methods. The present invention further relates to the uses of peroxyformic acid for treating a variety of targets, e.g., target water, including target water used in connection with oil- and gas-field operations. The present invention further relates to methods for reducing or removing H2S or iron sulfide in the treated water source, improving clarity of the treated water source, or reducing the total dissolved oxygen or corrosion in the treated water source, using peroxyformic acid, including peroxyformic acid generated in situ.
Type:
Grant
Filed:
October 11, 2017
Date of Patent:
March 19, 2019
Assignee:
ECOLAB USA INC.
Inventors:
Ramakrishnan Balasubramanian, Junzhong Li, Richard Staub, Victor Keasler, Brian Bennett, Allison Brewster
Abstract: Embodiments herein relate to animal feed preservatives including byproducts containing levulinic acid and methods of making and using the same. In an embodiment, a method of making an animal feed preservative is included. The method can include obtaining an acidic byproduct of a manufacturing process. The acidic byproduct can include at least about 1% by weight levulinic acid or a salt thereof. The method can further include mixing the acidic byproduct with a base to form the animal feed preservative. The animal feed preservative can include at least about 5 wt. % of the acid byproduct. In various embodiments, a method of reducing the amount of mycotoxins formed in an animal feed product during storage is included. In various embodiments, an animal feed preservative or supplement is included. Other embodiments are also included herein.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
February 5, 2019
Assignee:
Hawkins, Inc.
Inventors:
Theodore R. Stern, Stephen G. Campano, Gary Carl Larson
Abstract: A composition for deterring intruders includes propionic acid, ammonia and water. A content of water in the composition is at least approximately 60% by weight. A system for spraying a composition comprises a nozzle configured to spray the composition in an area inside a building. The composition comprises propionic acid, ammonia and water. A content of water in the composition is at least approximately 60% by weight.
Abstract: The present disclosure provides methods for treating or preventing malaria by administration of abscisic acid, analogs or pharmaceutical salts thereof to a mammalian subject infected with or at risk of exposure to Plasmodium. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasitemia and gametocytemia in a mammalian subject and/or reducing transmission of Plasmodium by a mosquito vector.
Type:
Grant
Filed:
October 14, 2016
Date of Patent:
December 18, 2018
Assignee:
The Regents Of The University Of California
Inventors:
Shirley Luckhart, Elizabeth K. K. Glennon
Abstract: Systems and methods to improve the detection and classification of inflammation in the eye are presented. The inflammatory markers in image data can be graded by comparing identified and extracted characteristics from the images with characteristics derived from a set of images of eyes from a general population of subjects. The image data can be divided into sub-regions for analysis to better isolate the true inflammatory markers from the impacts of cataracts or other opacities. In another embodiment, the location of an imaging beam can be controlled to minimize the impact of lens opacities from the collected data used to analyze the inflammation state of an eye.
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
December 4, 2018
Assignee:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Abstract: The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.
Abstract: The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.
Abstract: A terminally sterilized aqueous calcium gluconate solution comprising 1 to 15 wt. % calcium gluconate and from 1 to 19 wt. parts of calcium saccharate per 100 wt. parts of calcium gluconate packaged in a flexible plastic container with the remainder water.
Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.
Abstract: Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
October 2, 2018
Assignee:
Strides Shasun Limited
Inventors:
Jeffrey Stuart Bergman, Sampathkumar Devarajan, Selvakumar Ramalingam, Anandsenthil Vel Palanisamy
Abstract: The present invention relates to intervertebral misalignment, such as scoliosis, spondylolisthesis, vertebral subluxation and vertebral fractures. A composition for use in the treatment of intervertebral misalignment is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
Abstract: The present invention relates to novel combined laundry detergent, bleach, and antimicrobial composition incorporating novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds used in compositions of the invention are storage stable, water soluble and have low to no odor. Compositions of the invention may be in the form of a liquid, a solid, or a gel. The sulfoperoxycarboxylic compounds useful in preparing compositions of the present invention can be formed from non-petroleum based renewable materials.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
September 18, 2018
Assignee:
Ecolab USA Inc.
Inventors:
David W. Gohl, Robert D. P. Hei, Thomas Merz, Peter Jens Forth, Matthias Kreysel, David D. McSherry, Junzhong Li, Jonathan P. Fast
Abstract: The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
September 4, 2018
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Longsheng Hu, Virginia Streusand Goldman, Josephine A. Minerva, Susan Wendling
Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.
Abstract: Methods for the generation of non-equilibrium solutions of peroxyacetic acid are disclosed. These methods comprise introducing triacetin and aqueous hydrogen peroxide to water, mixing, and then adding an aqueous source of an alkali metal or earth alkali metal hydroxide. Triacetin is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid.
Abstract: There is provided protein biomarkers and methods for their use in diagnosing and treating Inflammatory Bowel Disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) as well as methods for assessing the severity of the diseases.
Type:
Grant
Filed:
April 3, 2017
Date of Patent:
June 19, 2018
Assignee:
UNIVERSITY OF OTTAWA
Inventors:
Daniel Figeys, Alain Stintzi, David R. Mack, Cheng-Kang Chiang, Amanda Elizabeth Starr
Abstract: A composition including a buffered lactic acid having a pH within the range of from 3.0 to 6.5 is disclosed. The composition is a lubricant composition and has a water activity of from 0.03 to 0.60. The friction between the absorbent product and the skin/mucous membrane of the user is reduced when in contact with the skin or mucous membrane of the user. An additional advantage is that the composition has a pH in the acidic range which is close to the pH of the skin and/or mucous membrane.
Abstract: Compositions and methods for the disinfection of surfaces are provided. The compositions include an alcohol and a peracid. The disinfectant composition is characterized by a pH of no more than about 5. Broad spectrum efficacy is achieved, and synergistic activity is exhibited against bacterial and fungal spores, including Clostridium difficile spores. The compositions and methods are also useful against conformationally altered prions, bacteria, fungi, and viruses.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
April 10, 2018
Assignee:
GOJO Industries, Inc.
Inventors:
James Edmund Bingham, Christopher M. Fricker, Michael J. Dolan
Abstract: The present invention provides methods for producing a non ?-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an ?-keto peracid and a non ?-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans.
Abstract: Disclosed are taxifolin derivative with superior antioxidant effect, a method of synthesizing the same and a cosmetic composition containing the same. In accordance with the method, taxifolin derivatives having higher antioxidant activity than taxifolin can be synthesized using lipoic acid. As such, a novel taxifolin derivative synthesized according to the present invention can exhibit anti-aging effects when used for cosmetics and the like.
Type:
Grant
Filed:
August 9, 2016
Date of Patent:
November 21, 2017
Assignee:
Yeomyung Biochem Co., Ltd.
Inventors:
Jae Duk Lee, Hyun Jin An, Da Hye Park, Yong Sub Yi, Yong Hwa Lee
Abstract: Methods for killing spores include contacting the spores with an aqueous solution containing performic acid. The contacting occurs at a temperature of less than or equal to about 35° C. for a period of time of less than or equal to about 15 seconds, and the contacting effects at least a 4 log reduction in a number of spores capable of reproduction, metabolism, and/or growth.
Abstract: There is provided pharmaceutical compositions suitable for topical application to the nail for the treatment of nail diseases such as onychomycosis, comprising a urea-based component, a diol component, such as propylene glycol, an organic acid component, such as lactic acid, and a triol component, such a glycerol. There is further provided methods of improving the storage stability of a pharmaceutical composition suitable for topical application to the skin and/or nails comprising such urea-based components, diol components, organic acid components, and, optionally, an aqueous base, which method comprises adding a triol component, such a glycerol, to that composition prior to said storage.
Type:
Grant
Filed:
January 29, 2015
Date of Patent:
October 10, 2017
Assignee:
Moberg Pharma AB
Inventors:
Ewa Karlsson, Sahar Feizollahi Ashkar, Peter Kaufmann